U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment

MW U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment

The U.S. government said this week it is halting distribution of Eli Lilly & Co.'s $(LLY)$ COVID-19 antibody treatment in six states due to the growing prevalence of the P.1 and B.1.351 variants there. Lilly's combination therapy of bamlanivimab and etesevimab "are not active against either the P.1 or B.1.351 variants," which were first identified in Brazil and South Africa, respectively, the Assistant Secretary for Preparedness and Response said Wednesday .